Cencora, Inc. (COR) fair value analysis
S&P 500 · Updated 2026-10-19
COR price how computed
Forward Fair Value verdict
Fairly valuedCOR is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $323.85
- Sector
- Healthcare
- 12-month range
- $252.74–$374.75
- Market cap
- $61.8B
- From 52-week high
- -13.6%
- Shares outstanding
- 191M
- Rank in Healthcare by discount to fair value
- #58 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Cencora, Inc. is a healthcare services company that distributes pharmaceuticals, medical supplies, and healthcare products to pharmacies, hospitals, and other healthcare providers. The company operates distribution networks across the United States and Canada.
COR currently ranks #58 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $61.8B
- P/E (trailing)
- 19x
- Revenue (TTM)
- $333B
- Net margin
- 0.8%
- EPS (TTM)
- $17.15
- Gross margin
- 4.3%
- Debt / equity
- 3.84
- Revenue growth (3-yr avg)
- 7.7%
- Shares outstanding
- 191M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Stable
- 52-week position
- The upper-middle quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 74 · overbought
- 50-day average
- $320.25
- 200-day average
- $317.48
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Dividends how computed
- Paid, last 12 months
- $2.40 per share (4 payments)
- Yield on last price
- 0.74%
- Consecutive years of increases
- 3
- Last ex-dividend date
- 2026-08-14
- Last payment date
- 2026-08-31
Earnings how computed
- Next earnings report
- 2026-11-04 (pre-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+2.5%)
2026-03 ▲ beat (+0.4%)
2025-12 ▲ beat (+1.0%)
2025-09 ▲ beat (+1.3%)
2025-06 ▲ beat (+4.2%)
2025-03 ▲ beat (+7.8%)
2024-12 ▲ beat (+6.0%)
2024-09 ▲ beat (+3.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 11 buy · 3 hold · 0 sell (14 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $368
- Target vs last price
- +13.6%
What our data shows for COR
- Our model validated 17 trailing price-to-earnings windows for COR, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $252.74–$374.75.
- The 14-day relative strength index sits at an overbought 74.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for COR
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the COR conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for COR in the Healthcare sector have shifted this week, with the Relative Strength Index moving from a neutral zone into overbought territory. The stock remains at a fairly valued assessment based on current valuation metrics. This change in momentum suggests increased buying pressure in the stock over the past week.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for COR in the Healthcare sector show that the company's sector discount rank improved from number 75 to number 69 this week. The current valuation verdict remains that COR is fairly valued. This improvement in ranking suggests COR is trading at a relatively better discount position compared to other Healthcare sector companies than it was in the prior week.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is COR stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), COR is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is COR's TickrTrends verdict?
COR's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does COR compare to other Healthcare stocks?
COR ranks #58 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is COR overbought or oversold?
COR's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.
Does COR pay a dividend?
Yes. COR paid $2.40 per share over the last twelve months (4 payments), a 0.74% yield on TickrTrends' last price, and has raised the annual total for 3 consecutive years. The last ex-dividend date was 2026-08-14.
When does COR report earnings next?
COR's next earnings report is scheduled for 2026-11-04 (pre-market), per the published earnings calendar.
Does COR usually beat earnings estimates?
Over its last 8 reported quarters COR beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about COR?
Of 14 analysts covering COR, 11 rate it a buy, 3 a hold and 0 a sell - buy-leaning, with a consensus price target of $368 (+13.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
COR vs A · COR vs ACHC · COR vs AVAH · COR vs CADL · COR vs COGT